Company Overview of Fumapharm AG
As of May 31, 2006, Fumapharm AG was acquired by Biogen Idec, Inc. Fumapharm AG, a pharmaceutical company, develops therapeutics. Its products include FUMADERM for the treatment of psoriasis; and BG-12 for the treatment of multiple sclerosis and psoriasis. The company was founded in 1983 and is headquartered in Luzern, Switzerland.
Founded in 1983
41 41 371 20 46
41 41 371 20 48
Key Executives for Fumapharm AG
Fumapharm AG does not have any Key Executives recorded.
Similar Private Companies By Industry
|Acino International AG||Europe|
|AL-S Pharma AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Fumapharm AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.